Revvity (NYSE:RVTY) Rating Lowered to Strong Sell at Zacks Research

Revvity (NYSE:RVTY) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research firms have also issued reports on RVTY. Wolfe Research initiated coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Sanford C. Bernstein assumed coverage on Revvity in a research report on Friday, June 26th. They set a “market perform” rating and a $115.00 price target on the stock. Robert W. Baird set a $117.00 price objective on Revvity in a report on Wednesday, May 6th. Evercore restated an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research report on Monday. Finally, JPMorgan Chase & Co. decreased their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $108.92.

Revvity Stock Down 0.7%

Shares of RVTY stock opened at $112.15 on Monday. Revvity has a twelve month low of $81.22 and a twelve month high of $118.30. The stock has a market cap of $12.51 billion, a P/E ratio of 53.66, a P/E/G ratio of 2.47 and a beta of 1.09. The stock has a 50 day moving average of $100.42 and a 200 day moving average of $98.36. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.01 EPS. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, sell-side analysts expect that Revvity will post 5.25 EPS for the current year.

Institutional Investors Weigh In On Revvity

Hedge funds have recently modified their holdings of the business. Ascentis Independent Advisors acquired a new position in Revvity during the first quarter worth about $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity in the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC lifted its stake in Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares in the last quarter. MUFG Securities EMEA plc acquired a new position in shares of Revvity during the 2nd quarter worth approximately $34,000. Finally, SJS Investment Consulting Inc. boosted its holdings in shares of Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.